CN105106937A - Application of nerve growth factor in preparation of drug used for promoting healing of fresh skin wound - Google Patents
Application of nerve growth factor in preparation of drug used for promoting healing of fresh skin wound Download PDFInfo
- Publication number
- CN105106937A CN105106937A CN201510315792.6A CN201510315792A CN105106937A CN 105106937 A CN105106937 A CN 105106937A CN 201510315792 A CN201510315792 A CN 201510315792A CN 105106937 A CN105106937 A CN 105106937A
- Authority
- CN
- China
- Prior art keywords
- wound
- skin
- preparation
- growth factor
- nerve growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses application of a nerve growth factor in preparation of a drug used for promoting healing of a fresh skin wound. The drug can improve an early healing area and healing rate of the wound and shorten complete healing time of the wound. Through external usage of the nerve growth factor, restoration of the fresh skin wound can be accelerated.
Description
Technical field
The present invention relates to medical art, particularly relate to nerve growth factor for the preparation of the purposes promoting the fresh wound healing medicine of skin.
Background technology
The generation of the fresh wound surface of skin is comparatively general, and often occur in daily productive labor process, various occupation, each age estate personnel can occur.Particularly fire fighters, armed police troops, coal miner etc., especially in major accident, be easy to the widespread skin wound caused, this wound is easy to the damage causing deep skin secondary, and its integrity is damaged, and can involve muscular tissue, skeleton and internal.Therefore, if wound repair can be promoted as soon as possible, alleviate patient suffering, shorten the course of disease, then mean a great.
At present, the medicine of many treatment skin traumas is had both at home and abroad, mainly Chinese medicine preparation and Western medicine preparation.Chinese medicine preparation uncertain therapeutic efficacy is cut, and Western medicine preparation is mainly based on sterilization, mainly plays anti-infective object, and after medication, the reparation of these wound faces is mainly by the tissue regeneration ability of body self, and the healing rate of wound is comparatively slow.
Therefore, fresh wound surface recovers to obtain Cytokines Drug to provide one to promote, accelerates wound healing speed, becomes problem demanding prompt solution.
Summary of the invention
The object of the present invention is to provide a kind of medicine that can be used for promoting the fresh wound healing of skin.
For achieving the above object, the invention provides a kind of nerve growth factor for the preparation of the application promoted in the fresh wound healing medicine of skin.
Further, the fresh wound surface of described skin refers to be caused by reasons such as operative incision, incision, scratch, lacerated wounds.
Further, the fresh wound surface of described skin is that skin integrity is impaired, and involves the wound surface of opening of muscle, skeleton.
Further, the fresh wound healing of described promotion skin refers to raising healing rate, shortens the complete healing time of wound.
Further, the step of to be added to by described nerve growth factor in the medicine of external preparation for skin is comprised.
Further, the dosage of described nerve growth factor is 500-3000AU/cm
2, be preferably 1000-3000AU/cm
2.
Applicant of the present invention is through innovative research, find nerve growth factor (NerveGrowthFactor, NGF) effect by other neurotrophic factor to direct or amplification stimulates keratinocyte proliferation and new vessels to be formed, thus contributes to the healing of wound surface.
Nerve growth factor grants the holostrome total loss skin wound of rat back, compared with negative control, to reduce normal rat wound healing area, improve healing rate, to shorten wound complete healing time effect more remarkable, has significant difference.Visible the present invention provides a kind of effectively new therapy approach for there being the patient of the fresh wound surface of skin, and then provides a kind of new method for the treatment of the various wound surface of skin.
According to embodiments of the invention, impose 500AU/cm
2, 1000AU/cm
2, 3000AU/cm
2nerve growth factor process have obvious effect to the wound healing of normal rat area in early stage, healing rate.Illustrate that external nerve growth factor can accelerate the reparation of the fresh wound surface of skin.
Accompanying drawing explanation
Fig. 1 is G1-7 Mus wound the 1st day and the 5th day, the 10th day, the 15th day recovery situation figure.
Fig. 2 is G2-16 Mus wound the 1st day and the 5th day, the 10th day, the 15th day recovery situation figure.
Fig. 3 is G3-29 Mus wound the 1st day and the 5th day, the 10th day, the 15th day recovery situation figure.
Fig. 4 is G431 Mus wound the 1st day and the 5th day, the 10th day, the 15th day recovery situation figure.
Fig. 5 is G5-58 Mus wound the 1st day and the 5th day, the 10th day, the 15th day recovery situation figure.
Detailed description of the invention
Be described below in detail embodiments of the invention, the example of described embodiment is shown in the drawings, and wherein same or similar label represents same or similar element or has element that is identical or similar functions from start to finish.Be exemplary below by the embodiment be described with reference to the drawings, be intended to for explaining the present invention, and can not limitation of the present invention be interpreted as.Unreceipted concrete technology or condition person in embodiment, according to the technology described by the document in this area or condition or carry out according to product description.Agents useful for same or the unreceipted production firm person of instrument, being can by the conventional products of commercial acquisition.
Embodiment 1: nerve growth factor is to the repair of the fresh wound surface in normal experimental rat back
1, experimental animal
Choose SPF level SD male rat 60 (purchased from Shanghai Si Laike Experimental Animal Center, the quality certification number: 2007000573991, the weight of animals: 280 ~ 350g when experiment starts), with under identical rearing conditions during experiment, (Animal House environment keeps temperature 23 ± 2 DEG C, humidity 40-70%, 12hr light and shade alternately.The raising of 5, animal per cage, changes weekly twice bedding and padding) conform 5-7 days.
2, EXPERIMENTAL DESIGN
Rat adaptability was fed after 5-7 days, and pentobarbital sodium intraperitoneal injection of anesthesia, to rat back position preserved skin, with iodophor disinfection, under aseptic condition, every rat back lower portion on the upper side has making 2 elliptical incision (3-5cm altogether
2) make the fresh wound healing model of holostrome total loss, hemostasis.By wound area and body weight, animal is divided into negative control group (hereinafter referred to as G1 group), processed group 1 (500AU/cm at random
2nGF stock solution, Wei Ming biological medicine company limited) (hereinafter referred to as G2 group), processed group 2 (1000AU/cm
2nGF stock solution) (hereinafter referred to as G3 group), processed group 3 (3000AU/cm
2nGF stock solution) (hereinafter referred to as G4 group), positive controls (150IU/cm
2external recombination human basic fibroblast growth factor-bFGF, the accurate word S20020023 of traditional Chinese medicines) (hereinafter referred to as G5 group).Often organize 10 rats, every rat two wound faces, administration volume is 0.05ml/cm
2.Each experimental group is evenly coated with each group accordingly by reagent once a day respectively, 15 days altogether.Negative control group is coated with normal saline and observes indices.Each group of rat within every 3 days, measure respectively wound area once, take pictures once.According to wound area adjustment administration volume.
3, Testing index
Wound healing situation: each group rat was taken pictures respectively at every 3 days and once records wound healing situation.See Fig. 1-5, get an often group Mus different time respectively and take pictures.Wherein Fig. 1 is G1-7 Mus wound the 1st day and the 5th day, the 10th day, the 15th day recovery situation figure.Fig. 2 is G2-16 Mus wound the 1st day and the 5th day, the 10th day, the 15th day recovery situation figure.Fig. 3 is G3-29 Mus wound the 1st day and the 5th day, the 10th day, the 15th day recovery situation figure.Fig. 4 is G4-31 Mus wound the 1st day and the 5th day, the 10th day, the 15th day recovery situation figure.Fig. 5 is G5-58 Mus wound the 1st day and the 5th day, the 10th day, the 15th day recovery situation figure.
Wound area and wound healing rate: respectively organizing rat measured wound area respectively at every 3 days, and calculated Wound healing rate.Wound area × 100% before wound healing rate (%)=(before treatment the rear wound area of wound area-treatment)/treatment
4, experimental result
4.1 nerve growth factor are on the impact of wound area
Compared with G1 (negative control group), G2 (NGF-500AU/cm
2) in average wound area and corresponding the contrasting of the 3rd day (3d), there were significant differences (p < 0.05).(see table 1)
Compared with G1 (negative control), G3 (NGF-1000AU/cm
2) in average wound area and corresponding the contrasting of the 3rd, five, ten day (3d, 5d, 10d), there were significant differences (p < 0.05).(see table 1)
Compared with G1 (negative control), G4 (NGF-3000AU/cm
2) third and fourth, five, seven, there were significant differences (p < 0.05) with corresponding contrasting for the average wound area of 12,15 days (3d, 4d, 5d, 7d, 12d, 15d).(see table 1)
Compared with G1 (negative control), G5 (positive control bFGF-150IU/cm
2) in average wound area and corresponding the contrasting of the 3rd, five, 15 days (3d, 5d, 15d), there were significant differences (p < 0.05).(see table 1)
Table 1 tested material affects table to normal rat wound area
Note:
data with represent,compare with matched group, * is P < 0.05
4.2 nerve growth factor are on the impact of wound healing situation
G2 (NGF-500AU/cm
2) compared with G1 (negative control), G2 (NGF-500AU/cm
2group) wound healing rate be significantly higher than G1 (negative control) (p < 0.05) at (3d) time point.(see table 2)
G3 (NGF-1000AU/cm
2) compared with G1 (negative control), G3 (NGF-1000AU/cm
2group) wound healing rate be significantly higher than G1 (negative control) (p < 0.05) at (3d, 5d, 10d) time point.(see table 2)
G4 (NGF-3000AU/cm
2) compared with G1 (negative control), G4 (NGF-3000AU/cm
2group) wound healing rate be significantly higher than G1 (negative control) (p < 0.05) at (3d, 5d, 12d, 15d) time point.(see table 2)
G5 (positive control bFGF-150IU/cm
2) compared with G1 (negative control), G5 (positive control bFGF-150IU/cm
2group) wound healing rate be significantly higher than G1 (negative control) (p < 0.05) at (3d, 15d) time point.(see table 2)
Table 2 tested material affects table to normal rat wound healing rate
Note:
data with represent,compare with matched group, * is P < 0.05
To sum up, three groups of process of external nerve growth factor stock solution, G2 (500AU/cm
2group), G3 (1000AU/cm2 group), G4 (3000AU/cm
2group) be less than G1 (negative control group) (p < 0.05) at the wound area of some time point, wound healing rate is significantly higher than G1 (negative control group) (p < 0.05), especially G4 (3000AU/cm
2dosage) there were significant differences compared with negative control group at multiple time point for group, demonstrates the effect of good promotion wound healing.
Statistics display imposes 500AU/cm
2, 1000AU/cm
2, 3000AU/cm
2nerve growth factor process have obvious effect to the wound healing of normal rat area in early stage, healing rate.
More than show, external nerve growth factor can accelerate the reparation of the fresh wound surface of skin.
Although illustrate and describe embodiments of the invention above, be understandable that, above-described embodiment is exemplary, can not be interpreted as limitation of the present invention, those of ordinary skill in the art can change above-described embodiment within the scope of the invention when not departing from principle of the present invention and aim, revising, replacing and modification.
Claims (6)
1. nerve growth factor is for the preparation of the purposes promoted in the fresh wound healing medicine of skin.
2. described in claim 1 for the preparation of the purposes promoted in skin fresh wound healing medicine, it is characterized in that, the fresh wound surface of described skin refers to be caused by operative incision, incision, scratch, lacerated wound.
3. described in claim 1 for the preparation of the purposes promoted in skin fresh wound healing medicine, it is characterized in that, the fresh wound surface of described skin is that skin integrity is impaired, and involves the wound surface of opening of muscle, skeleton.
4. described in claim 1 for the preparation of the purposes promoted in skin fresh wound healing medicine, it is characterized in that, the fresh wound healing of described promotion skin refers to raising healing rate, shortens the complete healing time of wound.
5. described in claim 1 for the preparation of the purposes promoted in skin fresh wound healing medicine, it is characterized in that, comprise the step of to be added to by described nerve growth factor in the medicine of external preparation for skin.
6. described in claim 5 for the preparation of the purposes promoted in skin fresh wound healing medicine, it is characterized in that, the dosage of described nerve growth factor is 500-3000AU/cm
2, be preferably 1000-3000AU/cm
2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510315792.6A CN105106937A (en) | 2015-06-10 | 2015-06-10 | Application of nerve growth factor in preparation of drug used for promoting healing of fresh skin wound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510315792.6A CN105106937A (en) | 2015-06-10 | 2015-06-10 | Application of nerve growth factor in preparation of drug used for promoting healing of fresh skin wound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105106937A true CN105106937A (en) | 2015-12-02 |
Family
ID=54655203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510315792.6A Pending CN105106937A (en) | 2015-06-10 | 2015-06-10 | Application of nerve growth factor in preparation of drug used for promoting healing of fresh skin wound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105106937A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108355071A (en) * | 2018-01-12 | 2018-08-03 | 昆明医科大学 | A kind of application process of red rice water extract in promoting wound repair |
| CN110538198A (en) * | 2019-08-30 | 2019-12-06 | 广东海洋大学 | application of Sipunculus nudus water extract in wound repair |
| CN110638836A (en) * | 2019-08-30 | 2020-01-03 | 广东海洋大学 | Application of water-soluble pearl powder in promoting wound healing |
-
2015
- 2015-06-10 CN CN201510315792.6A patent/CN105106937A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 史春梦等: "全身放射损伤对伤口早期局部组织核转录因子NF-κB活性的影响", 《中华放射医学与防护杂志》 * |
| 史春梦等: "神经生长因子同时促进放创复合伤小鼠创面愈合和造血恢复的实验研究", 《中华放射医学与防护杂志》 * |
| 李皓桓等: "吡咯喹啉醌对放创性皮肤损伤促愈合研究", 《中华放射医学与防护杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108355071A (en) * | 2018-01-12 | 2018-08-03 | 昆明医科大学 | A kind of application process of red rice water extract in promoting wound repair |
| CN110538198A (en) * | 2019-08-30 | 2019-12-06 | 广东海洋大学 | application of Sipunculus nudus water extract in wound repair |
| CN110638836A (en) * | 2019-08-30 | 2020-01-03 | 广东海洋大学 | Application of water-soluble pearl powder in promoting wound healing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020202719B2 (en) | Administration of tasimelteon under fasted conditions | |
| Pettersson et al. | Pain relief by wound infiltration with bupivacaine or high-dose ropivacaine after inguinal hernia repair | |
| JP2023113650A5 (en) | ||
| CN105106937A (en) | Application of nerve growth factor in preparation of drug used for promoting healing of fresh skin wound | |
| CN108721320A (en) | The application of micromolecule hyaluronic acid segment | |
| CN105520934B (en) | Application of michelia lactone dimethylamine | |
| TWI740051B (en) | Method for treating stroke or reducing nerve injury | |
| JP2019503335A (en) | Use of Dimethylamino Micheliolide | |
| CN103405751A (en) | Composition with cell repairing function and preparation method and application thereof | |
| CN103705910B (en) | A kind of Ziconotide injection hypodermic implant and preparation method thereof | |
| Huggins et al. | Cardiac arrest from succinylcholine-induced hyperkalemia | |
| CN102631667B (en) | Nerve regeneration promotion injection and preparation method thereof | |
| CN102813914B (en) | Medicinal composition used for treating or preventing cerebrovascular disease and related diseases | |
| Wilsey et al. | Automated blood sampling in a canine telemetry cardiovascular model | |
| CN105030765A (en) | Pain easing medicinal composition and application thereof | |
| Sirivongs et al. | Experiences on bedside Tenckhoff catheter implantation | |
| RU2009129507A (en) | METHOD FOR TREATING ONCOLOGICAL DISEASES | |
| CN101879171A (en) | Oral liquid preventing and curing gallinaceous leucocyto zoonosis and preparation method thereof | |
| RU2337704C1 (en) | Method of postsurgery rehabilitation of fishes | |
| CN105326840B (en) | A kind of combination medicine containing qinghaosu | |
| CN107007621A (en) | It is a kind of that there is pharmaceutical composition for the treatment of skin injury effect and its preparation method and application | |
| RU2018118617A (en) | BACLOFENUS FOR INTRAVENOUS ADMINISTRATION AND METHODS OF TREATMENT | |
| US20040047929A1 (en) | Method to enhance the immune system and used for the prevention and treatment of asthma | |
| Singla et al. | Comparative analysis of muscle splitting versus muscle dividing incision in open cholecystectomy | |
| Aghdam et al. | Investigating the Effectiveness of Ketorolac in Controlling Pain after Abdominal Surgeries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151202 |
|
| RJ01 | Rejection of invention patent application after publication |